Sophia E Chrysostomou, Sandra Eder, Isabella Pototschnig, Anna-Lena Mayer, Martina Derler, Marion Mussbacher, Silvia Schauer, Dongxu Zhang, Dongmei Yan, Gennie Liu, Gerald Hoefler, Thomas Weichhart, Paul W Vesely, Lingbing Zhang, Martina Schweiger
BACKGROUND: Cancer-associated cachexia (CAC) is a debilitating syndrome associated with poor quality of life and reduced life expectancy of cancer patients. CAC is characterized by unintended body weight reduction due to muscle and adipose tissue loss. A major hallmark of CAC is systemic inflammation. Several non-steroidal anti-inflammatory drugs (NSAIDs) have been suggested for CAC treatment, yet no single medication has proven reliable. R-ketorolac (RK) is the R-enantiomer of a commonly used NSAID...
February 1, 2024: Journal of Cachexia, Sarcopenia and Muscle